Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer by Yat-Fung Chow, Hou-Hsuan Cheng, Ming-Huang Chen

Subjects: Get full text

Identifying factors for pembrolizumab eligibility in head and neck cancer by Satoru Miyamaru, Daizo Murakami, Kohei Nishimoto, Yorihisa Orita

Subjects: “…Pembrolizumab…”
Get full text

Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC) by Iadalin Ryntathiang, Mukesh Kumar Dharmalingam Jothinathan

Subjects: Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Subjects: “…Pembrolizumab…”
Get full text

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives by Bujnak AC, File B, Tewari KS

Subjects: Get full text

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma by Yuan Yao, Yiyi Yan, Vera J. Suman, Allan B. Dietz, Courtney L. Erskine, Anastasios Dimou, Svetomir N. Markovic, Svetomir N. Markovic, Robert R. McWilliams, Heather N. Montane, Matthew S. Block, Matthew S. Block

Subjects: Get full text

Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review by Beata Mayer, Pavel Babál, Lucia Krivošíková

Subjects: “…Pembrolizumab…”
Get full text

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre by Maria João Santos, Filipa Ferro, Andrea Machado, Ana Sofia Vilariça, Direndra Hasmucrai, Paula Alves

Subjects: Get full text

Concomitant exposure to benzodiazepines during pembrolizumab-based therapy for advanced non-small-cell lung cancer: a propensity-score matched analysis of monitoring agency data by Fabrizio Nelli, Enzo Maria Ruggeri, Antonella Virtuoso, Diana Giannarelli, Armando Raso, Federica Natoni, Gloria Pessina, Daniele Remotti, Mario Giovanni Chilelli, Carlo Signorelli, Agnese Fabbri

Subjects: Get full text

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC ex vivo by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival by Jana Wellhausen, Louisa Röhl, Michael Berszin, Irene Krücken, Irene Krücken, Veit Zebralla, Veit Zebralla, Markus Pirlich, Markus Pirlich, Matthaeus Stoehr, Matthaeus Stoehr, Susanne Wiegand, Susanne Wiegand, Susanne Wiegand, Andreas Dietz, Andreas Dietz, Theresa Wald, Theresa Wald, Gunnar Wichmann, Gunnar Wichmann

Subjects: “…PD-1:PD-L1 immune-checkpoint inhibitor (ICI) pembrolizumab…”
Get full text